Tremor Amplitude as a Digital Biomarker

Tremor amplitude is the size of involuntary rhythmic movement, measured continuously by motion sensors rather than rated on a five point scale once in clinic.

Status
Validated
Unit
mm or deg/s
Data type
Composite
Sensor
Accelerometer + gyroscope
Worn
Wrist

Evidence maturity

Graded with the V3 framework: whether the sensor measures accurately, whether the algorithm has been validated against a reference standard, and whether the measure has been shown to matter clinically.

Verification
Established
Analytical validation
Established
Clinical validation
Emerging

Kinematic amplitude correlates well with clinical rating scales and resolves finer change than ordinal scoring allows. What is missing is an established threshold for how much change matters to a person.

What is Tremor Amplitude

Tremor is involuntary rhythmic oscillation of a body part, and amplitude is how large that oscillation is. Clinically it has always been graded by observation on ordinal rating scales, where a clinician watches a patient hold a posture or perform a task and assigns a score from zero to four. Motion sensors replace that judgement with a physical quantity: displacement or angular velocity, recorded continuously, alongside the frequency of the oscillation and the proportion of time tremor is present.

The difference is not only precision. An ordinal scale has four or five usable steps, which puts a floor on how small a treatment effect a trial can detect. A kinematic measurement is continuous, so it can resolve change that a rating scale rounds away, and it can be collected while the person goes about a normal day rather than only while they are being watched.

How it is measured

Amplitude is derived from accelerometer and gyroscope signals, usually worn on the wrist or the affected limb. The signal is band pass filtered around the tremor frequency band, conventionally three to twelve hertz depending on tremor type, to separate oscillation from voluntary movement, and amplitude is then computed within that band. Because tremor type matters, classification guidance from the International Parkinson and Movement Disorder Society distinguishes rest, postural and kinetic tremor, and each is elicited by a different condition, which is why structured tasks are still used alongside passive recording.

Validation has largely been done against clinical rating scales. Sensor derived amplitude correlates well with those scales while resolving finer gradations, and dedicated systems for structured in clinic and at home tremor assessment have been evaluated in essential tremor and Parkinson's disease.

Clinical use

The main uses are treatment response and progression. In essential tremor and Parkinson's disease, tremor amplitude quantifies the effect of medication, deep brain stimulation and focused ultrasound with sensitivity a rating scale cannot match. In drug trials, continuous measurement also captures how amplitude varies across a dosing cycle rather than only at the moment of assessment.

Passive monitoring adds something separate: it describes how much tremor a person actually experiences during ordinary activity, which is closer to the burden they report than a scored task is. These measures are reported alongside disease specific instruments such as the Hoehn and Yahr stage and the Parkinson's Disease Questionnaire, since the sensor measures the movement while the questionnaire measures what that movement costs the person.

Regulatory status

No standalone regulatory qualification as an endpoint. Dedicated motion sensor systems for tremor assessment have been used in registered trials, and tremor rating scales remain the primary endpoint in most of them.

Limitations

Amplitude depends heavily on the task and posture. A resting tremor and a postural tremor recorded in the same person produce different numbers, so passive recordings must be interpreted with context or they conflate conditions that clinicians deliberately separate.

Sensor placement changes the value, and wrist measurement does not represent tremor elsewhere in the body. Voluntary movement can be misclassified as tremor and the reverse, particularly during activity. Most importantly, the amount of change in amplitude that matters to a person has not been established for most contexts, so a statistically detectable reduction is not automatically a clinically meaningful one. The tremor rating scales most trials still report as their primary endpoint are not in this library, which is a real gap in the instrument bridge for this measure.

References

  • Bhatia KP, et al. Consensus statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018. pubmed.ncbi.nlm.nih.gov
  • Elble R, et al. Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord. 2013. pubmed.ncbi.nlm.nih.gov
  • Mostile G, et al. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010. pubmed.ncbi.nlm.nih.gov
  • Elble RJ, et al. Tremor rating scales and laboratory tools for assessing tremor. J Neurol Sci. 2022. pubmed.ncbi.nlm.nih.gov
Devices that capture it
Related instruments

The tremor specific rating scales that trials use as primary endpoints are not currently in this library, which is a known gap. The Hoehn and Yahr stage and the Parkinson's Disease Questionnaire are listed because they describe the disease stage and the burden that tremor contributes to.

Use case
Monitoring · Response
Collect Tremor Amplitude and other digital biomarkers in one workflow. Or turn your research into a new digital biomarker?
Capture sensor derived motor data alongside disease specific patient reported outcomes in one workflow.

Collect your digital biomarker data in no time all under your own brand

Collect meaningful digital biomarker data from your patients with ease. Our platform connects with wearables, smartphones, and other digital health devices, helping you capture continuous, real world data for research or clinical use all within your own branded experience.

Learn More

Connect your Data Sources

Connect wearables, smartphones, and digital health devices to collect relevant biomarker data directly from your patients.
Learn More
We Guide

Collect Data Continuously

Capture passive and active digital biomarker data such as activity, sleep, heart rate, mobility, and other vital signals over time.
Learn More

Collect the Data that Matters

Collect the digital health data most relevant to your research or clinical program. Choose the measurements and data points that support your specific study objectives and use case.
Learn More

Monitor the Full Patient Journey

Collect longitudinal biomarker data throughout the patient journey, from onboarding and baseline assessment to ongoing monitoring and follow up.
Learn More
Build your own biomarker, gather
evidence and commerclise
support screenshot
Pallete Paints

Rapidly design and configure complex studies in one place.

Set up your study without the technical friction. Easily define and configure all the critical data points you need to collect from patient reported forms and clinical tests to remote wearables using our intuitive, centralised platform.
Clinical Trial Builder

Capture unified, multimodal data with automated workflows.

Utilise WeGuide Engage to build your required dataset effortlessly. Keep participants and clinicians actively involved through automated prompts, ensuring high compliance and consistent data capture across all modalities.
We Guide
We Guide
Toggle Right

Evaluate clinical algorithms instantly with AI powered tools.

Bypass the technical bottlenecks with our biomarker development studio. Seamlessly create, score, and evaluate complex algorithms with the click of a button, turning raw data into validated insights without bespoke coding.
We Guide

Distribute directly via our Class IIb certified platform.

Seamlessly transition from research to revenue. Commercialise your digital biomarker instantly on our regulatory approved infrastructure, making it immediately available for pharma, clinical trials, and real-world interventions.